Compound News and Research

RSS

Possible cure for Parkinson's disease

Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others.

4 Nov 2009

Third quarter 2009 financial results announced by Affymax

Affymax, Inc. today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008.

4 Nov 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.

4 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

Scientists identify compounds that hold promise for treating parasitic infection

Using an unconventional approach that they designed, University of Pittsburgh drug discoverers and their collaborators at Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection that many consider one of the world's most overlooked diseases.

4 Nov 2009

H1N1 vaccine: Discussions and debates

You can't avoid H1N1 media coverage. It's front-page news on the web, the presses, the airways. Vaccine details, or lack of, are spurring discussion and debate. And a lot of people are in a quandary about whether or not to have the H1N1 shot based on their personal views and the information disseminated for public knowledge.

4 Nov 2009

Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms

Texas State University and Orizon Research Institute announced the signing of an agreement today that will permit University Researchers to continue efforts through in vivo testing to further determine the potential and effectiveness of ALKA-V6, a compound which has shown remarkable ability to kill cancer cells and inhibit the HIV virus in laboratory experiments.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

AMRI announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company will proceed into preclinical development. AMRI will receive a $750,000 payment from Bristol-Myers Squibb for the completion of this milestone, marking the fifth milestone payment in the ongoing research collaboration between the two companies.

3 Nov 2009

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Community pharmacists have stepped up to meet the shortage of Tamiflu by compounding doses for children suffering from the H1N1 flu virus, but they are struggling with supply problems and insurance plans, according to the National Community Pharmacists Association.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced that it has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population.

2 Nov 2009

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.

2 Nov 2009

Pulmatrix raises $30.2 million through Series B financing

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.

2 Nov 2009

Requests to compound liquid Tamiflu have steadily increased over the past couple of weeks

There has been a lot of information about the importance of taking preventative measures against H1N1, primarily through vaccination. But what if a person has already contracted H1N1? What if that person is a young child?

31 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

Study: HSP inhibitor could stop tumor formation and extend survival

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential.

30 Oct 2009

Fiscal 2009 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the year ended July 31, 2009.

30 Oct 2009

Compound News and Research

Possible cure for Parkinson's disease

Third quarter 2009 financial results announced by Affymax

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Scientists identify compounds that hold promise for treating parasitic infection

H1N1 vaccine: Discussions and debates

Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Phase 1 study of STX107 for Fragile X syndrome begins

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix raises $30.2 million through Series B financing

Requests to compound liquid Tamiflu have steadily increased over the past couple of weeks

Eisai reports global Phase III study results of eribulin mesylate

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Study: HSP inhibitor could stop tumor formation and extend survival

Fiscal 2009 results announced by Helix BioPharma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News